Hydroxyurea

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Realizing Effectiveness Across Continents With Hydroxyurea (REACH)

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Realizing Effectiveness Across Continents With Hydroxyurea

Alternative Dosing And Prevention of Transfusions (ADAPT)

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Stroke Prevention in Nigeria 2 Trial